You are here

Johnson & Johnson forecasts profit decline this year on competition

Its hepatitis C drug Olysio faces competition from Gilead Sciences' Harvoni that combines two drugs in one pill

New York

JOHNSON & JOHNSON (J&J), the world's biggest maker of healthcare products, forecast lower earnings in 2015 as competition cuts into revenue for some of its best-selling drugs. The shares slumped the most in three months.

Adjusted profit this year will reach US$6.12